Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals

NCT04681430 is registered in ClinicalTrials.gov with Heinrich-Heine University, Duesseldorf as lead sponsor.

NCT NCT04681430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04681430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reconvalescent Plasma / Camostat Mesylate Early in Sars-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals
Lead sponsor
Heinrich-Heine University, Duesseldorf
Phase
Phase 2
Overall status
Completed
Start date
January 8, 2021
Completion date
October 29, 2021
Enrollment
22 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, sars-cov-2 acute respiratory disease, sars-cov-2 infection, sars-cov-2 pcr test positive